Turning Point Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Turning Point Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 2 currently recruiting 1 completed early-phase tilt upper quartile by trial count

Turning Point Therapeutics: 7 sponsored US clinical trials, 2 recruiting.

Turning Point Therapeutics sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Metastatic Solid Tumors, with 3 trials.

Upper-quartile sponsor footprint

Turning Point Therapeutics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 1

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

NCT04094610
RECRUITING Phase 1

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

NCT03093116
ACTIVE NOT RECRUITING Phase 1

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

NCT03993873
COMPLETED Phase 1

Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

NCT05001516
TERMINATED Phase 1

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

NCT05071183
TERMINATED Phase 1

A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

NCT04849273
TERMINATED Phase 1

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

NCT04161391

Phase Distribution

PhaseTrial count
Phase 1 7

Therapeutic Areas

Metastatic Solid Tumors 3
Locally Advanced Solid Tumors 2
MET Gene Alterations 1
Primary CNS Tumors 1
Lymphoma 1
Advanced Solid Tumor 1

What is open in the Turning Point Therapeutics pipeline

2 recruiting of 7 indexed (29% open); 1 completed (14%).

Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Metastatic Solid Tumors (3 trials), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Turning Point Therapeutics: open-pipeline peers nationwide

Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.

Turning Point Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30%40% Total trials Recruiting share Turning Point Therapeutics3M4Life Research89bioAbbott Diagnostics DivisionAlabama Physical Therapy & AcupunctureAlloSourceAlnylam PharmaceuticalsAnnovis Bio
Turning Point Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Turning Point Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 29% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Turning Point Therapeutics page

7 registered trials is a research-attention snapshot, not an endorsement of Turning Point Therapeutics or any single study.

  • 2 of Turning Point Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Metastatic Solid Tumors is the condition Turning Point Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Metastatic Solid Tumors trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Turning Point Therapeutics pipeline card: 7 registered trials from official public datasets.Report a data error.